Regional Chemotherapy for Inoperable Liver Metastases
Name of the Trial
Why This Trial Is Important
In IHP, the flow of blood into and out of the liver is temporarily isolated from the body's circulatory system and high doses of anticancer drugs, such as melphalan, are infused directly into the liver through the hepatic artery. This technique allows the delivery of high doses of chemotherapy to liver metastases while sparing the rest of the body from drug exposure.
In this trial, doctors are testing a type of IHP called percutaneous isolated hepatic arterial perfusion (PHP) in patients with liver metastases from ocular (eye) or cutaneous (skin) melanoma. In PHP, catheters inserted through the skin are used to deliver drugs to the liver, block the flow of blood from the liver, and then remove the drugs. In contrast with IHP, this technique avoids the complications of major surgery and can be repeated if necessary.
"With this study, we're comparing treatment with systemic chemotherapy versus a minimally invasive method of delivering chemotherapy regionally to the affected organ," said Dr. Pingpank. “We hope to establish regional chemotherapy as a standard of care for patients with metastatic ocular melanoma, a disease for which no standard therapy currently exists."
Who Can Join This Trial
Study Site and Contact Information
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.